Briefing
Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.
Of 135 people, 26% were ctDNA-positive after surgery. The primary endpoint in ctDNA-negative people was not met (2-year relapse-free rate 88%, below the 92% threshold).
- Design: Evidence level 1
- Assay: Not named in the abstract